[VT – NYC], June 22, 2025 | On Sunday evening, high-net-worth investors gathered at Manhattan’s renowned restaurant for an exclusive, invitation-only investor dinner hosted by BioCopy AG, a Swiss biotech company revolutionizing cancer immunotherapy through artificial intelligence. CEO Dr. Matthias Wiedenfels presented the company’s cutting-edge platform and announced the final opportunity to join its $24 million Series A funding round.
💼 Private Investment Opportunity Now Open
BioCopy is currently closing the final $14 million allocation of its Series A round, with strong interest from existing backers and select new investors. The round offers access to a high-potential, AI-powered drug discovery platform targeting a vast untapped oncology market.
🔬 Game-Changing AI Platform Targeting pHLA Cancer Markers
- Scientific Innovation: BioCopy’s proprietary technology focuses on pHLA targets—a novel class of cancer-specific markers found inside cells and previously deemed “undruggable.” These targets represent 75% of all solid tumors, offering an enormous first-mover advantage.
- AI Acceleration: The company’s integrated AI platform drastically reduces development time and cost, compared to traditional TCR-T therapies.
- Breakthrough Validation: Early preclinical data shows significantly improved efficacy and selectivity over existing approaches, with minimal off-target toxicity.
👨⚕️ World-Class Leadership & Track Record
- Dr. Matthias Wiedenfels, CEO, previously led Germany’s STADA in completing Europe’s largest biotech acquisition ($5.5B in 2018).
- Scientific team includes a Nobel Laureate and top immunology researchers from Germany and Switzerland.
- The company expects multiple licensing deals by 2027, each valued up to $300M, with IPO or M&A exit on the roadmap.
📊 Investment Highlights
| Metric | Details |
|---|---|
| 💸 Round | Series A |
| 💰 Target | $24M total ($14M remaining) |
| 🏷️ Valuation | $250M–$280M (PwC-validated) |
| 💵 Share Price | $3.50–$4.00 |
| 📈 Exit Timeline | 2027 IPO or licensing milestone |
| 🎯 Use of Proceeds | IND readiness for 3 lead programs |
Participation is limited to accredited investors only under Regulation D exemptions.
🌍 Why BioCopy Matters Now
- Massive Market Opportunity: The intracellular cancer target market is estimated at $48B, yet remains virtually untapped.
- Regulatory Advantages: BioCopy benefits from FDA’s support for non-animal early-stage testing, shortening development timelines.
- De-risked Business Model: Revenue generated through pharma licensing rather than internal commercialization.
📍 About the Event
The dinner provided a private setting for select guests to engage directly with BioCopy’s executive team, exploring the scientific and financial aspects of the platform.
🏁 Final Word
BioCopy represents a rare opportunity at the intersection of AI, immunotherapy, and blue-ocean oncology markets. With a proven leadership team, first-in-class platform, and clear exit strategy, the company is poised to become a global leader in next-generation cancer therapeutics.
